# BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications

- URL: https://theranews.net/blog/2026-04-16-biomednewsbreaks-nrx-pharmaceuticals-inc-nasdaq-nrxp-forms-nrx-defense-systems-s-44025c/
- Published: 2026-04-16
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: financialcontent
- Original report: https://www.financialcontent.com/article/nnwire-2026-4-15-biomednewsbreaks-nrx-pharmaceuticals-inc-nasdaq-nrxp-forms-nrx-defense-systems-subsidiary-to-advance-neuroplastic-therapies-for-military-and-government-applications
- Topics: depression
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

> NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression and PTSD, announced the formation of NRx Defense Systems Inc., a Florida-based research and development subsidiary dedicated to advancing combined neuroplastic treatments using D-cycloser

---
NRx Pharmaceuticals announced the formation of NRx Defense Systems Inc., a Florida-based research and development subsidiary dedicated to advancing neuroplastic treatments combining D-cycloserine and transcranial magnetic stimulation supported by robotic-enabled neuronavigation. The subsidiary will be led by Dr. Dennis McBride, with support from Chief Medical Innovation Officer Dr. Joshua Brown.

## Goals and Partnerships

NRx Defense Systems aims to pursue non-dilutive government and institutional funding while developing deployable solutions for military and first responder use. The subsidiary is developing a prototype in partnership with Zeta Surgical Inc., expected to be unveiled at the Clinical TMS Society annual meeting in June 2026.

NRx Pharmaceuticals is a biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for suicidal ideation in depression, including bipolar depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression.

NRx has filed an Abbreviated New Drug Application and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner's National Priority Voucher Program for treating suicidal ideation in patients with depression, including bipolar depression.

---

*This article is an AI-assisted summary. All facts and figures are drawn from the original report: [https://www.financialcontent.com/article/nnwire-2026-4-15-biomednewsbreaks-nrx-pharmaceuticals-inc-nasdaq-nrxp-forms-nrx-defense-systems-subsidiary-to-advance-neuroplastic-therapies-for-military-and-government-applications](https://www.financialcontent.com/article/nnwire-2026-4-15-biomednewsbreaks-nrx-pharmaceuticals-inc-nasdaq-nrxp-forms-nrx-defense-systems-subsidiary-to-advance-neuroplastic-therapies-for-military-and-government-applications)*